A detailed history of Simplex Trading, LLC transactions in I Mab stock. As of the latest transaction made, Simplex Trading, LLC holds 417 shares of IMAB stock, worth $446. This represents 0.0% of its overall portfolio holdings.

Number of Shares
417
Holding current value
$446
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$1.03 - $1.72 $429 - $717
417 New
417 $0
Q1 2024

Apr 25, 2024

BUY
$1.54 - $2.37 $123 - $189
80 Added 2000.0%
84 $0
Q4 2023

Feb 02, 2024

SELL
$1.21 - $1.9 $1,229 - $1,930
-1,016 Reduced 99.61%
4 $0
Q3 2023

Nov 01, 2023

SELL
$1.18 - $3.06 $661 - $1,716
-561 Reduced 35.48%
1,020 $1,000
Q2 2023

Aug 04, 2023

BUY
$2.95 - $3.85 $64 - $84
22 Added 1.41%
1,581 $4,000
Q1 2023

Apr 27, 2023

SELL
$3.08 - $7.39 $24,874 - $59,681
-8,076 Reduced 83.82%
1,559 $5,000
Q4 2022

Feb 02, 2023

BUY
$3.22 - $4.86 $27,006 - $40,760
8,387 Added 672.04%
9,635 $40,000
Q3 2022

Nov 04, 2022

BUY
$4.01 - $12.34 $5,004 - $15,400
1,248 New
1,248 $5,000
Q2 2022

Aug 03, 2022

SELL
$8.27 - $18.43 $14,083 - $31,386
-1,703 Closed
0 $0
Q1 2022

May 02, 2022

BUY
$12.54 - $46.93 $20,064 - $75,088
1,600 Added 1553.4%
1,703 $27,000
Q4 2021

Feb 23, 2022

SELL
$45.28 - $74.5 $7,335 - $12,069
-162 Reduced 61.13%
103 $4,000
Q3 2021

Oct 28, 2021

SELL
$57.18 - $84.43 $5,718 - $8,443
-100 Reduced 27.4%
265 $22,000
Q2 2021

Aug 12, 2021

BUY
$47.86 - $83.95 $7,896 - $13,851
165 Added 82.5%
365 $30,000
Q1 2021

Apr 26, 2021

BUY
$44.38 - $63.97 $8,876 - $12,794
200 New
200 $9,000

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $88.9M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.